Estrella Pb Ratio from 2010 to 2025

ESLAW Stock   0.09  0.00  0.00%   
Estrella Immunopharma PB Ratio yearly trend continues to be fairly stable with very little volatility. PB Ratio is likely to outpace its year average in 2025. During the period from 2010 to 2025, Estrella Immunopharma PB Ratio regression line of quarterly data had mean square error of  392.92 and geometric mean of  35.23. View All Fundamentals
 
PB Ratio  
First Reported
2010-12-31
Previous Quarter
8.38670041
Current Value
8.81
Quarterly Volatility
29.0319974
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Estrella Immunopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Estrella Immunopharma's main balance sheet or income statement drivers, such as Tax Provision of 2 K, Depreciation And Amortization of 246.2 K or Selling General Administrative of 3.9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 8.81. Estrella financial statements analysis is a perfect complement when working with Estrella Immunopharma Valuation or Volatility modules.
  
Check out the analysis of Estrella Immunopharma Correlation against competitors.
For more information on how to buy Estrella Stock please use our How to Invest in Estrella Immunopharma guide.

Latest Estrella Immunopharma's Pb Ratio Growth Pattern

Below is the plot of the Pb Ratio of Estrella Immunopharma over the last few years. It is Estrella Immunopharma's PB Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Estrella Immunopharma's overall financial position and show how it may be relating to other accounts over time.
Pb Ratio10 Years Trend
Slightly volatile
   Pb Ratio   
       Timeline  

Estrella Pb Ratio Regression Statistics

Arithmetic Mean(40.03)
Geometric Mean35.23
Coefficient Of Variation(72.53)
Mean Deviation24.34
Median(56.26)
Standard Deviation29.03
Sample Variance842.86
Range65.3164
R-Value0.75
Mean Square Error392.92
R-Squared0.56
Significance0.0008
Slope4.58
Total Sum of Squares12,643

Estrella Pb Ratio History

2025 8.81
2023 9.06
2022 8.39

About Estrella Immunopharma Financial Statements

Estrella Immunopharma investors use historical fundamental indicators, such as Estrella Immunopharma's Pb Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Estrella Immunopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
PB Ratio 8.39  8.81 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Estrella Stock Analysis

When running Estrella Immunopharma's price analysis, check to measure Estrella Immunopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Estrella Immunopharma is operating at the current time. Most of Estrella Immunopharma's value examination focuses on studying past and present price action to predict the probability of Estrella Immunopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Estrella Immunopharma's price. Additionally, you may evaluate how the addition of Estrella Immunopharma to your portfolios can decrease your overall portfolio volatility.